AstraZeneca succeeds in late-stage trial for myasthenia gravis therapy
Source: SeekingAlpha
2025-07-24 08:27:12 ET
More on AstraZeneca
- AstraZeneca: Just What The Doctor Ordered
- AstraZeneca: Navigating Challenges Across Geographies Well
- AstraZeneca: Fascinating Company With Lofty Ambitions - Just Not A Buy Yet
- RFK Jr. formally orders removal of thimerosal from all flu vaccines
- Sanofi, Astra succeed in U.S. real-world study for Beyfortus
Read the full article on Seeking Alpha
For further details see:
AstraZeneca succeeds in late-stage trial for myasthenia gravis therapy
Zai Lab Limited
NASDAQ: ZLAB
ZLAB Trading
-1.63% G/L:
$18.365 Last:
202,921 Volume:
$18.85 Open:
ZLAB Latest News
February 26, 2026 07:00:00 am
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
ZLAB Stock Data
$2,174,273,322
105,108,310
0.9%
39
N/A
Biotechnology & Life Sciences
Healthcare
CN
Shanghai
